Navigation auf uzh.ch

Suche

Epidemiology, Biostatistics and Prevention Institute

Preoperative smoking cessation program in patients undergoing intermediate to high-risk surgery

Background: At present, effectively implementing smoking cessation programs in the health care system constitutes a major challenge. A unique opportunity to initiate smoking cessation focuses on smokers scheduled for surgery. These patients are not only highly motivated to quit smoking but also likely to benefit from a reduction in postoperative complications which may translate into a decrease of costs. Nevertheless, surgical patients are not routinely informed about the benefits of preoperative smoking cessation. Potential reasons for this missed opportunity may be the lack of time and training of surgeons and anaesthesiologists. We therefore aim to analyse the impact of a preoperative high-intensity smoking cessation intervention on surgical complications up to a 90-day postoperative period in patients of various surgical disciplines. The hypothesis is that a preoperative smoking cessation program improves outcomes in smokers undergoing intermediate to high-risk surgery.

Methods: The present study is a single-centre, randomized trial with two parallel groups of smokers scheduled for surgery comparing surgery alone and surgery with preoperative smoking cessation. We plan to randomize 251 patients. The primary objective is to compare complications between patients with an institutional multifaceted smoking cessation intervention starting 4 weeks before surgery compared to patients in the advice-only group (control group) within a 90-day postoperative period. The primary endpoint is the Comprehensive Complication Index (CCI®) within 90 days of surgery. Secondary outcomes include the length of hospital stay, cost of care, quality of life, smoking abstinence, and reduction in nicotine consumption.

Discussion: The hypothesis is that a preoperative smoking cessation program improves outcomes in smokers undergoing surgery.

Trial registration: BASEC #2021-02004; ClinicalTrials.gov: NCT05192837. Registered on January 14, 2022.

The published trial protocol can be found here.

Weiterführende Informationen

Team

Ulrike Held (Project Leader)
Milo Puhan (Project Leader)
Beatrice Cortonesi

Funding

Swiss Cancer League